The combination of PTPN11 and NF1 mutations may thus give rise to malignant transformation in NF1 cells, and SHP-2 inhibition by BRAP is a potential therapeutic strategy for NF1-MPNST. Here, PTPN11 is linked to malignant peripheral nerve sheath tumor.